<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35614233</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Long COVID after breakthrough SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>1461</StartPage><EndPage>1467</EndPage><MedlinePgn>1461-1467</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-022-01840-0</ELocationID><Abstract><AbstractText>The post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-also referred to as Long COVID-have been described, but whether breakthrough SARS-CoV-2 infection (BTI) in vaccinated people results in post-acute sequelae is not clear. In this study, we used the US Department of Veterans Affairs national healthcare databases to build a cohort of 33,940 individuals with BTI and several controls of people without evidence of SARS-CoV-2 infection, including contemporary (n&#x2009;=&#x2009;4,983,491), historical (n&#x2009;=&#x2009;5,785,273) and vaccinated (n&#x2009;=&#x2009;2,566,369) controls. At 6&#x2009;months after infection, we show that, beyond the first 30&#x2009;days of illness, compared to contemporary controls, people with BTI exhibited a higher risk of death (hazard ratio (HR)&#x2009;=&#x2009;1.75, 95% confidence interval (CI): 1.59, 1.93) and incident post-acute sequelae (HR&#x2009;=&#x2009;1.50, 95% CI: 1.46, 1.54), including cardiovascular, coagulation and hematologic, gastrointestinal, kidney, mental health, metabolic, musculoskeletal and neurologic disorders. The results were consistent in comparisons versus the historical and vaccinated controls. Compared to people with SARS-CoV-2 infection who were not previously vaccinated (n&#x2009;=&#x2009;113,474), people with BTI exhibited lower risks of death (HR&#x2009;=&#x2009;0.66, 95% CI: 0.58, 0.74) and incident post-acute sequelae (HR&#x2009;=&#x2009;0.85, 95% CI: 0.82, 0.89). Altogether, the findings suggest that vaccination before infection confers only partial protection in the post-acute phase of the disease; hence, reliance on it as a sole mitigation strategy may not optimally reduce long-term health consequences of SARS-CoV-2 infection. The findings emphasize the need for continued optimization of strategies for primary prevention of BTI and will guide development of post-acute care pathways for people with BTI.</AbstractText><CopyrightInformation>&#xa9; 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Aly</LastName><ForeName>Ziyad</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-2600-0434</Identifier><AffiliationInfo><Affiliation>Clinical Epidemiology Center, Research and Development Service, VA Saint Louis Health Care System, St. Louis, MO, USA. zalaly@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Research and Education Foundation of Saint Louis, St. Louis, MO, USA. zalaly@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. zalaly@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nephrology Section, Medicine Service, VA Saint Louis Health Care System, St. Louis, MO, USA. zalaly@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Public Health, Washington University in Saint Louis, St. Louis, MO, USA. zalaly@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowe</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Center, Research and Development Service, VA Saint Louis Health Care System, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Research and Education Foundation of Saint Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2457-9382</Identifier><AffiliationInfo><Affiliation>Clinical Epidemiology Center, Research and Development Service, VA Saint Louis Health Care System, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Research and Education Foundation of Saint Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2022 Jun;606(7916):852-853. doi: 10.1038/d41586-022-01702-2</RefSource><PMID Version="1">35725828</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="Y">Nervous System Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35614233</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pii">10.1038/s41591-022-01840-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264. doi: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Juthani PV, et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect. Dis. 2021;21:1485&#x2013;1486. doi: 10.1016/S1473-3099(21)00558-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00558-2</ArticleId><ArticleId IdType="pmc">PMC8423430</ArticleId><ArticleId IdType="pubmed">34506735</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon DF, Ndhlovu LC. Vaccine breakthrough infections with SARS-CoV-2 variants. N. Engl. J. Med. 2021;385:e7. doi: 10.1056/NEJMc2107808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2107808</ArticleId><ArticleId IdType="pubmed">34077640</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe, B., Xie, Y., Xu, E. &amp; Al-Aly, Z. Kidney outcomes in Long COVID. J. Am. Soc. Nephrol.32, 2851&#x2013;2862 (2021)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8806085</ArticleId><ArticleId IdType="pubmed">34470828</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat. Commun. 2021;12:6571. doi: 10.1038/s41467-021-26513-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26513-3</ArticleId><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y., Xu, E. &amp; Al-Aly, Z. Risks of mental health outcomes in people with Covid-19: cohort study. BMJ376, e068993 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8847881</ArticleId><ArticleId IdType="pubmed">35172971</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty SE, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373:n1098. doi: 10.1136/bmj.n1098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1098</ArticleId><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18:e1003773. doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416&#x2013;427. doi: 10.1016/S2215-0366(21)00084-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693. doi: 10.1136/bmj.n693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan NA. The road to addressing Long Covid. Science. 2021;373:491&#x2013;493. doi: 10.1126/science.abg7113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg7113</ArticleId><ArticleId IdType="pubmed">34326224</ArticleId></ArticleIdList></Reference><Reference><Citation>Kind AJH, Buckingham WR. Making neighborhood-disadvantage metrics accessible&#x2014;the neighborhood atlas. N. Engl. J. Med. 2018;378:2456&#x2013;2458. doi: 10.1056/NEJMp1802313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1802313</ArticleId><ArticleId IdType="pmc">PMC6051533</ArticleId><ArticleId IdType="pubmed">29949490</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019;365:l1580. doi: 10.1136/bmj.l1580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l1580</ArticleId><ArticleId IdType="pmc">PMC6538974</ArticleId><ArticleId IdType="pubmed">31147311</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y., Bowe, B., Maddukuri, G. &amp; Al-Aly, Z. Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study. BMJ371, m4677 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7735416</ArticleId><ArticleId IdType="pubmed">33323357</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y. et al. Comparative effectiveness of sodium-glucose cotransporter 2 inhibitors vs sulfonylureas in patients with type 2 diabetes. JAMA Intern. Med.181, 1043&#x2013;1053 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240007</ArticleId><ArticleId IdType="pubmed">34180939</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai M, et al. Temporal trends in incidence rates of lower extremity amputation and associated risk factors among patients using Veterans Health Administration services from 2008 to 2018. JAMA Netw. Open. 2021;4:e2033953. doi: 10.1001/jamanetworkopen.2020.33953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.33953</ArticleId><ArticleId IdType="pmc">PMC7823225</ArticleId><ArticleId IdType="pubmed">33481033</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai M, Bowe B, Xie Y, Al-Aly Z. Temporal trends of COVID-19 mortality and hospitalisation rates: an observational cohort study from the US Department of Veterans Affairs. BMJ Open. 2021;11:e047369. doi: 10.1136/bmjopen-2020-047369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-047369</ArticleId><ArticleId IdType="pmc">PMC8370839</ArticleId><ArticleId IdType="pubmed">34400452</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Yan Y, Al-Aly Z. Burden of cause-specific mortality associated with PM2.5 air pollution in the United States. JAMA Netw. Open. 2019;2:e1915834. doi: 10.1001/jamanetworkopen.2019.15834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.15834</ArticleId><ArticleId IdType="pmc">PMC6902821</ArticleId><ArticleId IdType="pubmed">31747037</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe, B. et al. Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19. Clin. J. Am. Soc. Nephrol.16, 14&#x2013;25 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7792643</ArticleId><ArticleId IdType="pubmed">33199414</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y. &amp; Ziyad, A.-A. Risks and burdens of incident diabetes in long COVID-19: a cohort study. Lancet Diabetes Endocrinol.10, 311&#x2013;321 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8937253</ArticleId><ArticleId IdType="pubmed">35325624</ArticleId></ArticleIdList></Reference><Reference><Citation>Spudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022;375:267&#x2013;269. doi: 10.1126/science.abm2052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm2052</ArticleId><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, A., Oda, G. &amp; Holodniy, M. COVID-19 vaccine breakthrough infections in Veterans Health Administration. Preprint at https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.09.23.21263864v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512&#x2013;522. doi: 10.1097/EDE.0b013e3181a663cc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181a663cc</ArticleId><ArticleId IdType="pmc">PMC3077219</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y, et al. Short term exposure to fine particulate matter and hospital admission risks and costs in the Medicare population: time stratified, case crossover study. BMJ. 2019;367:l6258. doi: 10.1136/bmj.l6258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l6258</ArticleId><ArticleId IdType="pmc">PMC6880251</ArticleId><ArticleId IdType="pubmed">31776122</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubert CE, et al. Best definitions of multimorbidity to identify patients with high health care resource utilization. Mayo Clin. Proc. Innov. Qual. Outcomes. 2020;4:40&#x2013;49. doi: 10.1016/j.mayocpiqo.2019.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocpiqo.2019.09.002</ArticleId><ArticleId IdType="pmc">PMC7011007</ArticleId><ArticleId IdType="pubmed">32055770</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP) Clinical Classifications Software Refined (CCSR). https://www.hcup-us.ahrq.gov/toolssoftware/ccsr/ccs_refined.jsp</Citation></Reference><Reference><Citation>Olvey EL, Clauschee S, Malone DC. Comparison of critical drug&#x2013;drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin. Pharmacol. Ther. 2010;87:48&#x2013;51. doi: 10.1038/clpt.2009.198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2009.198</ArticleId><ArticleId IdType="pubmed">19890252</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene M, Steinman MA, McNicholl IR, Valcour V. Polypharmacy, drug&#x2013;drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J. Am. Geriatr. Soc. 2014;62:447&#x2013;453. doi: 10.1111/jgs.12695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.12695</ArticleId><ArticleId IdType="pmc">PMC4043391</ArticleId><ArticleId IdType="pubmed">24576251</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights. Am. J. Epidemiol. 2019;188:250&#x2013;257. doi: 10.1093/aje/kwy265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwy265</ArticleId><ArticleId IdType="pubmed">30189042</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA. 2020;323:2417&#x2013;2418. doi: 10.1001/jama.2020.7819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.7819</ArticleId><ArticleId IdType="pubmed">32369102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21:383&#x2013;388. doi: 10.1097/EDE.0b013e3181d61eeb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181d61eeb</ArticleId><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi X, Miao W, Tchetgen ET. A selective review of negative control methods in epidemiology. Curr. Epidemiol. Rep. 2020;7:190&#x2013;202. doi: 10.1007/s40471-020-00243-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40471-020-00243-4</ArticleId><ArticleId IdType="pmc">PMC8118596</ArticleId><ArticleId IdType="pubmed">33996381</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>